Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chronic lymphocytic leukemia

HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chronic lymphocytic leukemia

US Patent 11813261 · Granted Nov 14, 2023

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Pharmaceutical combinations comprising a histone deacetylase inhibitor and a CD32024
Pharmaceutical combinations comprising a histone deacetylase inhibitor and a CD32024
Pharmaceutical combinations comprising a histone deacetylase inhibitor and epoth2024
Pharmaceutical combinations comprising a histone deacetylase inhibitor and an au2024
Pharmaceutical combinations comprising a histone deacetylase inhibitor and a pro2022
Pharmaceutical combinations comprising a histone deacetylase inhibitor and a pro2022
Pharmaceutical combinations comprising a histone deacetylase inhibitor and an au2022
Pharmaceutical combinations comprising a histone deacetylase inhibitor and a CD32022
Pharmaceutical combinations comprising a histone deacetylase inhibitor and a CD32022
Methods of use and pharmaceutical combinations of histone deacetylase inhibitors2022
Increasing expression of interferon regulated genes with combinations of histone2022
Methods of use and pharmaceutical combinations of HDAC inhibitors with BET inhib2022